- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.06. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| NASUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 09.06. | Nasus Pharma reports positive preclinical data for NS003 | 1 | Investing.com | ||
| 26.05. | Nasus Pharma Ltd - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 26.03. | Citizens senkt Kursziel für Nasus Pharma auf 18 US-Dollar | 1 | Investing.com Deutsch | ||
| 26.03. | Citizens cuts Nasus Pharma stock price target to $18 on valuation | 1 | Investing.com | ||
| 25.03. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 25.03. | Nasus Pharma legt positive Phase-2-Daten für Adrenalin-Nasenspray vor | 1 | Investing.com Deutsch | ||
| 25.03. | Nasus Pharma reports Phase 2 results for intranasal epinephrine | 1 | Investing.com | ||
| 25.03. | Nasus Pharma Ltd - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 25.03. | Nasus Pharma, Ltd.: Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update | 228 | GlobeNewswire (Europe) | Recent Phase 2 topline results demonstrate NS002's potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study... ► Artikel lesen | |
| 18.03. | What's Going On With Nasus Pharma Stock On Wednesday | 1 | Benzinga.com | ||
| 16.03. | Nasus Pharma Stock Hits 52-Week Low - Here's Why | 4 | Benzinga.com | ||
| 16.03. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 16.03. | Nasus Pharma reports faster epinephrine delivery in Phase 2 study | 1 | Investing.com | ||
| 16.03. | Nasus Pharma, Ltd.: Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen with Accelerated Speed to Therapeutic Threshold | 269 | GlobeNewswire (Europe) | NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4%... ► Artikel lesen | |
| 09.03. | Nasus Pharma to present phase 2 data for intranasal epinephrine | 1 | Investing.com | ||
| 09.03. | Nasus Pharma, Ltd.: Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum | 2 | GlobeNewswire (USA) | ||
| 04.03. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.03. | Nasus Pharma Ltd - F-1, Registration statement for certain foreign private issuers | 2 | SEC Filings | ||
| 24.02. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QUANTUM BIOPHARMA | 2,754 | -1,57 % | Quantum BioPharma Provides Corporate Update | THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, July 07, 2026... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 60,10 | -2,53 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 3,510 | -0,57 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| OPKO HEALTH | 1,230 | +3,36 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results | MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first... ► Artikel lesen | |
| OPUS GENETICS | 3,360 | -2,33 % | Opus Genetics, Inc.: Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results | RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the "Company", "Opus Genetics" or "Opus"), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| PROTHENA | 7,940 | -2,00 % | Prothena Corporation plc: Prothena Reports First Quarter 2026 Financial Results and Business Highlights | Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million
Prothena updates... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 3,650 | -0,41 % | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute | WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx" or the "Company") today issued the following statement in response to recent public claims made... ► Artikel lesen | |
| NEUROGENE | 34,400 | -1,15 % | Morning Market Movers: Neurogene, Duolingo, Xponential Fitness, Emergent BioSolutions See Big Swings | WASHINGTON (dpa-AFX) - At 6:22 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ORIC PHARMACEUTICALS | 9,336 | -1,73 % | ORIC Pharmaceuticals: ORIC Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates | Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026 Reported rinzimetostat... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 0,351 | -0,20 % | NSE - REVIVA PHARMACEUTICALS HOLDINGS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| OMNIAB | 2,300 | +0,44 % | OmniAb, Inc. - 8-K, Current Report | ||
| ONKURE THERAPEUTICS | 4,250 | -0,70 % | OnKure Therapeutics, Inc.: OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Ka Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026 | ||
| PROCESSA PHARMACEUTICALS | 2,210 | +2,31 % | Processa Pharmaceuticals, Inc. - 10-Q, Quarterly Report | ||
| PRF TECHNOLOGIES | 1,355 | +0,37 % | PRF Technologies Ltd. - 6-K, Report of foreign issuer | ||
| ANBIO BIOTECHNOLOGY | 8,050 | -14,81 % | Anbio Biotechnology - 6-K, Report of foreign issuer |
Das Unternehmen NASUS PHARMA LTD kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NASUS PHARMA LTD finden Sie auf Wallstreet Online.